Cancer immunotherapy: exploiting neoepitopes
- PMID: 26032267
- PMCID: PMC4528051
- DOI: 10.1038/cr.2015.66
Cancer immunotherapy: exploiting neoepitopes
Abstract
The efficacy of cancer vaccines has long been hampered by insufficient definition of tumor-specific antigens. A recent study by Kreiter et al. published in Nature has provided a blueprint for a patient-tailored approach to develop individualized RNA vaccines.
Comment on
-
Mutant MHC class II epitopes drive therapeutic immune responses to cancer.Nature. 2015 Apr 30;520(7549):692-6. doi: 10.1038/nature14426. Epub 2015 Apr 22. Nature. 2015. PMID: 25901682 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
